Pages that link to "Q40293476"

The following pages link to Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC. (Q40293476):

Displaying 44 items.

• Targeting the Fc receptor in autoimmune disease (Q27002843) (← links)
• Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies (Q28069362) (← links)
• Glycomics profiling of Chinese hamster ovary cell glycosylation mutants reveals N-glycans of a novel size and complexity (Q30937269) (← links)
• Double knockdown of alpha1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC (Q33307815) (← links)
• Molecular cloning, characterization, genomic organization and promoter analysis of the α1,6-fucosyltransferase gene (fut8) expressed in the rat hybridoma cell line YB2/0 (Q33786180) (← links)
• Rapid assays for lectin toxicity and binding changes that reflect altered glycosylation in mammalian cells (Q33965300) (← links)
• Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor (Q34584868) (← links)
• Characterization of N-Linked Glycosylation in a Monoclonal Antibody Produced in NS0 Cells Using Capillary Electrophoresis with Laser-Induced Fluorescence Detection (Q35052763) (← links)
• Sialic acid methylation refines capillary electrophoresis laser-induced fluorescence analyses of immunoglobulin G N-glycans of ovarian cancer patients (Q35165824) (← links)
• EB66 cell line, a duck embryonic stem cell-derived substrate for the industrial production of therapeutic monoclonal antibodies with enhanced ADCC activity (Q35232342) (← links)
• Neuroprotection with a brain-penetrating biologic tumor necrosis factor inhibitor (Q35429973) (← links)
• Enzymatic functionalization of a nanobody using protein insertion technology (Q35597176) (← links)
• Comprehensive N-Glycan Profiling of Cetuximab Biosimilar Candidate by NP-HPLC and MALDI-MS. (Q36245448) (← links)
• Evaluation of glycosylation for quality assurance of antibody pharmaceuticals by capillary electrophoresis (Q37273597) (← links)
• Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies (Q37323537) (← links)
• Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC (Q37403194) (← links)
• Production of therapeutic antibodies with controlled fucosylation (Q37672128) (← links)
• Engineering mammalian cells in bioprocessing - current achievements and future perspectives (Q37730868) (← links)
• Optimizing therapeutic antibody function: progress with Fc domain engineering (Q37804830) (← links)
• GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins (Q38028654) (← links)
• Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types (Q38308978) (← links)
• Amino acid and glucose metabolism in fed-batch CHO cell culture affects antibody production and glycosylation (Q38956580) (← links)
• Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering. (Q39279968) (← links)
• Fucose content of monoclonal antibodies can be controlled by culture medium osmolality for high antibody-dependent cellular cytotoxicity (Q39484103) (← links)
• Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study. (Q39559611) (← links)
• Current progress in innovative engineered antibodies (Q40077818) (← links)
• Disruption of alpha-mannosidase processing induces non-canonical hybrid-type glycosylation (Q40139612) (← links)
• Challenges with afucosylation content in antibody-based drugs: Guidance provided by mathematical modeling (Q41491243) (← links)
• Development and validation of an antibody-dependent cell-mediated cytotoxicity-reporter gene assay (Q41868216) (← links)
• Advantages of AlaGln as an additive to cell culture medium: use with anti-CD20 chimeric antibody-producing POTELLIGENT™ CHO cell lines (Q42153431) (← links)
• GlycoDelete engineering of mammalian cells simplifies N-glycosylation of recombinant proteins. (Q42825895) (← links)
• Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase (Q42966864) (← links)
• Separation of nonfucosylated antibodies with immobilized FcγRIII receptors (Q46360891) (← links)
• Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy (Q49592680) (← links)
• A novel bicistronic gene design couples stable cell line selection with a fucose switch in a designer CHO host to produce native and afucosylated glycoform antibodies (Q50199955) (← links)
• Development of a pre-glycoengineered CHO-K1 host cell line for the expression of antibodies with enhanced Fc mediated effector function. (Q50200755) (← links)
• Identifying the differences in mechanisms of mycophenolic acid controlling fucose content of glycoproteins expressed in different CHO cell lines (Q51738172) (← links)
• Lec13 (Q54902419) (← links)
• Ms704 (Q54906807) (← links)
• Fc engineering of anti-Nectin-2 antibody improved thrombocytopenic adverse event in monkey. (Q54943207) (← links)
• Improving Immunotherapy Through Glycodesign (Q59132146) (← links)
• Immune Correlate-Guided HIV Vaccine Design (Q59357079) (← links)
• The "less-is-more" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity (Q88590150) (← links)
• How to select IgG subclasses in developing anti-tumor therapeutic antibodies (Q94547635) (← links)